Nyrada’s Lead Drug Cuts Liver Tumour Volume 57% in Combination Trial
Xolatryp delivers proof-of-concept anti-tumour results in preclinical liver cancer model
Nyrada Inc. (ASX: NYR) has released positive results from a preclinical oncology study evaluating its lead drug candidate Xolatryp® in a liver cancer model. The combination of Xolatryp with doxorubicin produced a 57% reduction in tumour volume at Day 14, compared with 41% for doxorubicin alone, representing an approximately 39% improvement in anti-tumour activity over the chemotherapy used independently. Xolatryp also demonstrated activity as a monotherapy, achieving a 32% tumour volume reduction relative to the vehicle control.
Alongside these results, Nyrada has lodged a provisional patent application for Xolatryp as an anti-cancer agent, complementary to the company’s earlier allowed composition of matter patent application.
James Bonnar, Managing Director and CEO, Nyrada Inc.
“This study demonstrates highly encouraging proof-of-concept of a clear additive benefit over a standard-of-care treatment, consistent with enhanced anti-tumour activity of doxorubicin when combined with Xolatryp.”
When big ASX news breaks, our subscribers know first
Understanding the science behind Xolatryp and liver cancer treatment
What are TRPC channels and why do they matter in cancer?
TRPC (Transient Receptor Potential Canonical) channels are proteins that regulate how calcium enters cells. Calcium plays a central role in controlling whether a cell survives, grows, or dies, making these channels relevant to cancer biology.
Specifically, TRPC6-mediated calcium signalling has been implicated in multidrug resistance in hepatocellular carcinoma (liver cancer) cells. In practical terms, this means that elevated TRPC6 activity may help tumour cells resist the effects of chemotherapy, reducing treatment efficacy. Published literature is increasingly linking TRPC channel activity to cancer progression and survival pathways more broadly.
Xolatryp is a potent inhibitor of TRPC3/6/7 ion channels, designed to limit excessive calcium entry into cells. By blocking these channels, Xolatryp may disrupt the survival mechanisms that allow cancer cells to evade treatment.
What is doxorubicin and why is it the benchmark?
Doxorubicin is an anthracycline chemotherapy drug that has been in clinical use since the 1970s. It is considered a “backbone drug” in oncology and is used as a first-line treatment across a wide range of cancers, including liver cancer, breast cancer, leukemias, lymphomas, sarcomas, and bladder, lung, and ovarian cancers.
The strategic significance of pairing Xolatryp with doxorubicin lies in doxorubicin’s entrenched position across multiple oncology settings. If Xolatryp can consistently enhance its anti-tumour activity, the compound could potentially be deployed as an adjunct to an already widely used standard-of-care drug.
How the study was designed
The study used a Huh7 cell-line derived rodent xenograft (CDX) model of liver cancer, a standard preclinical benchmark for assessing tumour growth inhibition. Huh7 cells were implanted subcutaneously, with treatment beginning once tumours reached 50–75 mm³. Tumour volumes were measured every other day for 14 days.
The four treatment arms were:
- Vehicle control (no treatment)
- Doxorubicin alone (administered twice weekly)
- Xolatryp alone (3 mg/kg, intratumorally, once daily)
- Doxorubicin combined with Xolatryp (3 mg/kg)
Plasma cardiac troponin I levels were also measured throughout the study, given doxorubicin’s well-documented association with cardiac injury in cancer patients.
Study results in detail — what the data shows
Tumour volume outcomes at Day 14
The combination arm delivered the strongest efficacy signal, with statistically significant tumour reduction observed as early as Day 4. The table below summarises the full efficacy dataset at the Day 14 endpoint.
| Treatment Group | Tumour Volume Reduction vs. Control | Statistical Significance | Onset of Significance | Key Observation |
|---|---|---|---|---|
| Vehicle control | 0% | — | — | Baseline comparator |
| Doxorubicin alone | 41% | p = 0.0006 from Day 6 | Day 6 | First-line standard of care |
| Xolatryp alone | 32% | p = 0.003 from Day 10 | Day 10 | Monotherapy activity confirmed |
| Doxorubicin + Xolatryp | 57% | p = 0.015 from Day 4 | Day 4 | Earliest onset; greatest magnitude |
The combination arm not only achieved the greatest absolute reduction in tumour volume, but also reached statistical significance earliest, at Day 4 compared with Day 6 for doxorubicin alone. The approximately 39% improvement in anti-tumour activity over doxorubicin monotherapy is characterised as consistent with an additive effect.
Safety profile and cardiac observations
Overall animal health, based on body weight assessments, was broadly consistent with expectations for this preclinical model. Two animals in the Xolatryp plus doxorubicin group died prematurely during the study. The announcement characterises these deaths as consistent with tumour lysis syndrome (TLS), a recognised clinical phenomenon in which rapid tumour cell death causes metabolic disturbances. TLS is associated with highly active anti-cancer therapies and is a manageable condition in the clinical setting.
On the cardiac safety front, animals receiving Xolatryp — both as a monotherapy and in the combination arm — demonstrated a favourable trend in cardiac troponin I levels relative to those receiving doxorubicin alone. This is a notable observation for investors: elevated troponin I is a marker of cardiac muscle injury, and doxorubicin-related cardiotoxicity is a known clinical limitation of the drug. A favourable troponin trend suggests Xolatryp may carry a cardioprotective profile alongside its anti-tumour activity, a characteristic that directly complements Nyrada’s ongoing Phase IIa STEMI trial.
The next major ASX story will hit our subscribers first
What comes next for Nyrada and Xolatryp
The announcement outlines a clear preclinical development roadmap for Xolatryp in oncology. Disclosed next steps include:
- Further preclinical evaluation of Xolatryp across additional tumour types where anthracyclines remain standard-of-care therapy
- Assessment in combination with other clinically relevant anti-cancer agents
- Development of clinically translatable systemic dosing strategies to optimise anti-tumour efficacy while maintaining tolerability
- An additional preclinical cardiomyopathy study to further assess the potential of Xolatryp as a differentiated adjunct therapy alongside anthracycline-based chemotherapy
- The provisional patent application for Xolatryp as an anti-cancer agent has been lodged, complementary to the earlier allowed composition of matter patent application
It is worth noting that Xolatryp is simultaneously progressing through a Phase IIa clinical trial for ST-Elevation Myocardial Infarction (STEMI), assessing the drug’s safety and preliminary efficacy in reducing myocardial ischemia reperfusion injury. These oncology findings represent a distinct and separate program, though the shared cardioprotective signal observed in both contexts is a point of scientific continuity.
For investors, the broader picture is one of a single clinical-stage asset accumulating evidence across multiple indication areas. Nyrada is building a multi-indication story around Xolatryp, supported by an expanding intellectual property estate. These liver cancer results represent early-stage, statistically significant proof-of-concept data. While substantial further work remains before any clinical translation, the combination efficacy data and favourable cardiac troponin signal provide a meaningful foundation for the next phase of development.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving healthcare announcement the moment it drops.